找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Neuroendocrine Neoplasia Management; New Approaches for D Giordano Beretta,Alfredo Berruti,Orlando Goletti Book 2021 Springer Nature Switze

[復制鏈接]
樓主: Adams
21#
發(fā)表于 2025-3-25 04:23:09 | 只看該作者
New Concepts in Pathologyct of the tumor cells and their proliferative activity in terms of the number of mitoses or proliferation index (Ki-67)..In PanNENs, for example, Ki-67 labeling index correlates significantly with overall survival and also with disease progression in patients with advanced neoplasms and with tumor r
22#
發(fā)表于 2025-3-25 11:14:05 | 只看該作者
23#
發(fā)表于 2025-3-25 12:34:34 | 只看該作者
24#
發(fā)表于 2025-3-25 19:25:08 | 只看該作者
25#
發(fā)表于 2025-3-25 23:53:31 | 只看該作者
New Approaches in Medical Therapiesnhibitors (pazopanib, cabozantinib, lenvatinib, axitinib, surufatinib). Moreover, immune checkpoint inhibitors have also been investigated in NETs, with some encouraging results in well-differentiated tumors, especially for lung NETs. Clinical studies have also investigated the efficacy of epigeneti
26#
發(fā)表于 2025-3-26 02:36:37 | 只看該作者
Locoregional Therapies of NEN On the other hand, liver ablation, firstly introduced for percutaneous imaging-guided approach and more recently also applied in open and laparoscopic setting, can provide eradication of liver metastases with less invasiveness than traditional surgery. Moreover, due to the high rate of relapse afte
27#
發(fā)表于 2025-3-26 07:17:32 | 只看該作者
NETs of the Lungin receptors (SSTRs). Systemic chemotherapy is reserved for those cases of locally advanced or metastatic disease, even if the standard regimen has not yet been defined. The role of targeted therapies in LCs remains still limited with the exception of the only approved drug (everolimus) in clinical
28#
發(fā)表于 2025-3-26 11:13:44 | 只看該作者
29#
發(fā)表于 2025-3-26 13:38:54 | 只看該作者
Treatment of Pancreatic Neuroendocrine TumorsRRT) are all adequately supported by strong scientific data, and there are no clear criteria that favor the choice of one treatment over the other. The decision-making process should be conducted as part of a multidisciplinary tumor board and must be based on some key elements: the Grade (G 1,2,3),
30#
發(fā)表于 2025-3-26 19:44:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 06:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
五寨县| 望城县| 万安县| 封丘县| 长武县| 晋江市| 桂阳县| 平南县| 吉林市| 涟源市| 阜新| 潼南县| 九寨沟县| 高青县| 郁南县| 晋江市| 炉霍县| 陆良县| 清水河县| 五大连池市| 台湾省| 宁强县| 牙克石市| 泗水县| 双流县| 土默特左旗| 亚东县| 中牟县| 加查县| 大宁县| 龙海市| 土默特左旗| 青海省| 九江市| 宜阳县| 抚州市| 宣武区| 达尔| 富平县| 临夏市| 宕昌县|